Ultragenyx Pharmaceutical
RARE
RARE
241 hedge funds and large institutions have $3.21B invested in Ultragenyx Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 89 increasing their positions, 81 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
0.32% more ownership
Funds ownership: 97.86% → 98.17% (+0.32%)
1% less call options, than puts
Call options by funds: $14.7M | Put options by funds: $14.9M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Holders
241
Holding in Top 10
2
Calls
$14.7M
Puts
$14.9M
Top Buyers
| 1 | +$123M | |
| 2 | +$52.3M | |
| 3 | +$16.3M | |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$15.2M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$14.4M |
Top Sellers
| 1 | -$56.6M | |
| 2 | -$44.4M | |
| 3 | -$34.6M | |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$33.9M |
| 5 |
Millennium Management
New York
|
-$32.6M |